Type Ii Diabetes clinical trials

Explore recruiting type ii diabetes clinical trials.

Recruiting type ii diabetes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Type Ii Diabetes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study comparing exposure of semaglutide and dapagliflozin dosed orally as mono-components versus in a fixed-dose combination

Germany

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

Austria

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes inadequately controlled on diet and exercise.

Italy, Hungary, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. oral solution formulations in healthy volunteers

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Type Ii Diabetes trials by city

Type Ii Diabetes in Toronto Type Ii Diabetes in Vancouver Type Ii Diabetes in Montreal Type Ii Diabetes in Calgary Type Ii Diabetes in Edmonton Type Ii Diabetes in Ottawa Type Ii Diabetes in Winnipeg Type Ii Diabetes in Quebec City Type Ii Diabetes in Hamilton Type Ii Diabetes in Kitchener Type Ii Diabetes in London Type Ii Diabetes in Halifax Type Ii Diabetes in New York Type Ii Diabetes in Los Angeles Type Ii Diabetes in Chicago Type Ii Diabetes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease